AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO - (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER 1 AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal. Patients with early-stage lung cancer are treated with the intention of cure; however, many relapse because treatment is limited to surgery and adjuvant chemotherapy. 2 Unprecedented clinical trial data show that osimertinib, the first approved targeted oral therapy in this setting, can reduce the risk of disease recurrence or death by 80% in patients with early-stage (IB-IIIA) EGFR mutation-positive NSCLC versus placebo.